Florida Senate - 2024 SB 700
By Senator Gruters
22-00740-24 2024700__
1 A bill to be entitled
2 An act relating to controlled substances; amending s.
3 893.03, F.S.; excepting from the list of Schedule I
4 controlled substances certain xylazine animal drug
5 products approved by the United States Food and Drug
6 Administration and used for certain purposes;
7 providing applicability; providing an effective date.
8
9 Be It Enacted by the Legislature of the State of Florida:
10
11 Section 1. Paragraph (c) of subsection (1) of section
12 893.03, Florida Statutes, is amended to read:
13 893.03 Standards and schedules.—The substances enumerated
14 in this section are controlled by this chapter. The controlled
15 substances listed or to be listed in Schedules I, II, III, IV,
16 and V are included by whatever official, common, usual,
17 chemical, trade name, or class designated. The provisions of
18 this section shall not be construed to include within any of the
19 schedules contained in this section any excluded drugs listed
20 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
21 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
22 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
23 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
24 Anabolic Steroid Products.”
25 (1) SCHEDULE I.—A substance in Schedule I has a high
26 potential for abuse and has no currently accepted medical use in
27 treatment in the United States and in its use under medical
28 supervision does not meet accepted safety standards. The
29 following substances are controlled in Schedule I:
30 (c) Unless specifically excepted or unless listed in
31 another schedule, any material, compound, mixture, or
32 preparation that contains any quantity of the following
33 hallucinogenic substances or that contains any of their salts,
34 isomers, including optical, positional, or geometric isomers,
35 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
36 salts of isomers, homologues, nitrogen-heterocyclic analogs,
37 esters, or ethers, if the existence of such salts, isomers, and
38 salts of isomers is possible within the specific chemical
39 designation or class description:
40 1. Alpha-Ethyltryptamine.
41 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
42 oxazoline).
43 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
44 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
45 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
46 6. Bufotenine.
47 7. Cannabis.
48 8. Cathinone.
49 9. DET (Diethyltryptamine).
50 10. 2,5-Dimethoxyamphetamine.
51 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
52 12. DMT (Dimethyltryptamine).
53 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
54 analog of phencyclidine).
55 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
56 15. N-Ethylamphetamine.
57 16. Fenethylline.
58 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
59 18. Ibogaine.
60 19. LSD (Lysergic acid diethylamide).
61 20. Mescaline.
62 21. Methcathinone.
63 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
64 23. PMA (4-Methoxyamphetamine).
65 24. PMMA (4-Methoxymethamphetamine).
66 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
67 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
68 27. MDA (3,4-Methylenedioxyamphetamine).
69 28. JB-336 (N-Methyl-3-piperidyl benzilate).
70 29. N,N-Dimethylamphetamine.
71 30. Parahexyl.
72 31. Peyote.
73 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
74 analog of phencyclidine).
75 33. Psilocybin.
76 34. Psilocyn.
77 35. Salvia divinorum, except for any drug product approved
78 by the United States Food and Drug Administration which contains
79 Salvia divinorum or its isomers, esters, ethers, salts, and
80 salts of isomers, esters, and ethers, if the existence of such
81 isomers, esters, ethers, and salts is possible within the
82 specific chemical designation.
83 36. Salvinorin A, except for any drug product approved by
84 the United States Food and Drug Administration which contains
85 Salvinorin A or its isomers, esters, ethers, salts, and salts of
86 isomers, esters, and ethers, if the existence of such isomers,
87 esters, ethers, and salts is possible within the specific
88 chemical designation.
89 37. Xylazine, except for a xylazine animal drug product
90 approved by the United States Food and Drug Administration and
91 the use of which conforms to the approved application or is
92 authorized under 21 U.S.C. s. 360b(a)(4). The manufacture,
93 importation, distribution, prescribing, or sale of xylazine for
94 human use is not subject to this exception.
95 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
96 (Thiophene analog of phencyclidine).
97 39. 3,4,5-Trimethoxyamphetamine.
98 40. Methylone (3,4-Methylenedioxymethcathinone).
99 41. MDPV (3,4-Methylenedioxypyrovalerone).
100 42. Methylmethcathinone.
101 43. Methoxymethcathinone.
102 44. Fluoromethcathinone.
103 45. Methylethcathinone.
104 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
105 yl)phenol) and its dimethyloctyl (C8) homologue.
106 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
107 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
108 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
109 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
110 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
111 naphthoyl)indole).
112 51. BZP (Benzylpiperazine).
113 52. Fluorophenylpiperazine.
114 53. Methylphenylpiperazine.
115 54. Chlorophenylpiperazine.
116 55. Methoxyphenylpiperazine.
117 56. DBZP (1,4-Dibenzylpiperazine).
118 57. TFMPP (Trifluoromethylphenylpiperazine).
119 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
120 Methylenedioxy-N-methylbutanamine).
121 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
122 60. 5-Hydroxy-N-methyltryptamine.
123 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
124 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
125 63. Methyltryptamine.
126 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
127 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
128 66. Tyramine (4-Hydroxyphenethylamine).
129 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
130 68. DiPT (N,N-Diisopropyltryptamine).
131 69. DPT (N,N-Dipropyltryptamine).
132 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
133 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
134 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
135 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
136 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
137 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
138 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
139 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
140 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
141 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
142 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
143 81. Butylone (3,4-Methylenedioxy-alpha
144 methylaminobutyrophenone).
145 82. Ethcathinone.
146 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
147 84. Naphyrone (Naphthylpyrovalerone).
148 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
149 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
150 87. 3,4-Methylenedioxy-propiophenone.
151 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
152 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
153 90. 3,4-Methylenedioxy-N-acetylcathinone.
154 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
155 92. 3,4-Methylenedioxy-N-acetylethcathinone.
156 93. Bromomethcathinone.
157 94. Buphedrone (alpha-Methylamino-butyrophenone).
158 95. Eutylone (3,4-Methylenedioxy-alpha
159 ethylaminobutyrophenone).
160 96. Dimethylcathinone.
161 97. Dimethylmethcathinone.
162 98. Pentylone (3,4-Methylenedioxy-alpha
163 methylaminovalerophenone).
164 99. MDPPP (3,4-Methylenedioxy-alpha
165 pyrrolidinopropiophenone).
166 100. MDPBP (3,4-Methylenedioxy-alpha
167 pyrrolidinobutyrophenone).
168 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
169 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
170 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
171 (Benocyclidine).
172 104. F-MABP (Fluoromethylaminobutyrophenone).
173 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
174 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
175 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
176 108. Me-EABP (Methylethylaminobutyrophenone).
177 109. Etizolam.
178 110. PPP (Pyrrolidinopropiophenone).
179 111. PBP (Pyrrolidinobutyrophenone).
180 112. PVP (Pyrrolidinovalerophenone) or
181 (Pyrrolidinopentiophenone).
182 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
183 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
184 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
185 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
186 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
187 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
188 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
189 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
190 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
191 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
192 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
193 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
194 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
195 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
196 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
197 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
198 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
199 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
200 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
201 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
202 ol).
203 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
204 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
205 methanol).
206 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
207 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
208 1,4-dione).
209 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
210 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
211 undecanamide).
212 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
213 undecanamide).
214 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
215 methyloctan-2-yl)phenol).
216 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
217 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
218 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
219 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
220 methoxyphenylacetyl)indole).
221 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
222 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
223 naphthalenylmethanone).
224 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
225 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
226 naphthalenylmethanone).
227 143. Pentedrone (alpha-Methylaminovalerophenone).
228 144. Fluoroamphetamine.
229 145. Fluoromethamphetamine.
230 146. Methoxetamine.
231 147. Methiopropamine.
232 148. Methylbuphedrone (Methyl-alpha
233 methylaminobutyrophenone).
234 149. APB ((2-Aminopropyl)benzofuran).
235 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
236 151. UR-144 (1-Pentyl-3-(2,2,3,3
237 tetramethylcyclopropanoyl)indole).
238 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
239 tetramethylcyclopropanoyl)indole).
240 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
241 tetramethylcyclopropanoyl)indole).
242 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
243 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
244 iodobenzoyl)indole).
245 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
246 carboxamide).
247 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
248 cyclohexylcarbamate).
249 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
250 cyclohexyl ester).
251 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
252 benzoxazin-4-one).
253 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
254 161. 2C-H (2,5-Dimethoxyphenethylamine).
255 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
256 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
257 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
258 methoxybenzyl)]phenethylamine).
259 165. MDMA (3,4-Methylenedioxymethamphetamine).
260 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
261 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
262 carboxylate).
263 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
264 carboxylate).
265 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
266 3-carboxamide).
267 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
268 pentylindazole-3-carboxamide).
269 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
270 (4-fluorobenzyl)indazole-3-carboxamide).
271 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
272 1-pentylindazole-3-carboxamide).
273 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
274 yl)-1-(fluoropentyl)indole-3-carboxamide).
275 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
276 methoxybenzyl)]phenethylamine).
277 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
278 methoxybenzyl)]phenethylamine).
279 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
280 (cyclohexylmethyl)indazole-3-carboxamide).
281 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
282 carboxylate).
283 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
284 3-carboxamide).
285 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
286 (fluoropentyl)indazole-3-carboxamide).
287 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
288 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
289 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
290 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
291 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
292 hexahydrobenzo[c]chromen-1-ol).
293 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
294 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
295 hexahydrobenzo[c]chromen-1-ol).
296 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
297 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
298 diol).
299 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
300 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
301 tetrahydro-6aH-benzo[c]chromen-1-ol).
302 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
303 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
304 187. MAPB ((2-Methylaminopropyl)benzofuran).
305 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
306 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
307 190. Synthetic Cannabinoids.—Unless specifically excepted
308 or unless listed in another schedule or contained within a
309 pharmaceutical product approved by the United States Food and
310 Drug Administration, any material, compound, mixture, or
311 preparation that contains any quantity of a synthetic
312 cannabinoid found to be in any of the following chemical class
313 descriptions, or homologues, nitrogen-heterocyclic analogs,
314 isomers (including optical, positional, or geometric), esters,
315 ethers, salts, and salts of homologues, nitrogen-heterocyclic
316 analogs, isomers, esters, or ethers, whenever the existence of
317 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
318 ethers, salts, and salts of isomers, esters, or ethers is
319 possible within the specific chemical class or designation.
320 Since nomenclature of these synthetically produced cannabinoids
321 is not internationally standardized and may continually evolve,
322 these structures or the compounds of these structures shall be
323 included under this subparagraph, regardless of their specific
324 numerical designation of atomic positions covered, if it can be
325 determined through a recognized method of scientific testing or
326 analysis that the substance contains properties that fit within
327 one or more of the following categories:
328 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
329 naturally contained in a plant of the genus Cannabis, the
330 synthetic equivalents of the substances contained in the plant
331 or in the resinous extracts of the genus Cannabis, or synthetic
332 substances, derivatives, and their isomers with similar chemical
333 structure and pharmacological activity, including, but not
334 limited to, Delta 9 tetrahydrocannabinols and their optical
335 isomers, Delta 8 tetrahydrocannabinols and their optical
336 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
337 isomers, or any compound containing a tetrahydrobenzo[c]chromene
338 structure with substitution at either or both the 3-position or
339 9-position, with or without substitution at the 1-position with
340 hydroxyl or alkoxy groups, including, but not limited to:
341 (I) Tetrahydrocannabinol.
342 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
343 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
344 ol).
345 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
346 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
347 ol).
348 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
349 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
350 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
351 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
352 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
353 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
354 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
355 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
356 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
357 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
358 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
359 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
360 (X) Parahexyl.
361 b. Naphthoylindoles, Naphthoylindazoles,
362 Naphthoylcarbazoles, Naphthylmethylindoles,
363 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
364 compound containing a naphthoylindole, naphthoylindazole,
365 naphthoylcarbazole, naphthylmethylindole,
366 naphthylmethylindazole, or naphthylmethylcarbazole structure,
367 with or without substitution on the indole, indazole, or
368 carbazole ring to any extent, whether or not substituted on the
369 naphthyl ring to any extent, including, but not limited to:
370 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
371 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
372 naphthoyl)indole).
373 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
374 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
375 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
376 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
377 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
378 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
379 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
380 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
381 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
382 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
383 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
384 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
385 naphthoyl)indole).
386 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
387 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
388 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
389 naphthoyl)indole).
390 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
391 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
392 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
393 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
394 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
395 naphthylmethyl]indole).
396 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
397 naphthoyl)indole).
398 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
399 naphthoyl)indole).
400 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
401 naphthoyl)indole).
402 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
403 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
404 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
405 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
406 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
407 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
408 naphthoyl)indole).
409 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
410 naphthoyl)indole).
411 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
412 naphthoyl)indole).
413 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
414 naphthoyl)indole).
415 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
416 naphthoyl)indole).
417 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
418 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
419 naphthoyl)indazole).
420 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
421 naphthoyl)indole).
422 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
423 naphthoyl)indole).
424 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
425 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
426 naphthoyl)carbazole).
427 c. Naphthoylpyrroles.—Any compound containing a
428 naphthoylpyrrole structure, with or without substitution on the
429 pyrrole ring to any extent, whether or not substituted on the
430 naphthyl ring to any extent, including, but not limited to:
431 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
432 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
433 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
434 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
435 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
436 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
437 naphthoyl)pyrrole).
438 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
439 naphthoyl)pyrrole).
440 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
441 naphthoyl)pyrrole).
442 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
443 naphthoyl)pyrrole).
444 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
445 naphthoyl)pyrrole).
446 d. Naphthylmethylenindenes.—Any compound containing a
447 naphthylmethylenindene structure, with or without substitution
448 at the 3-position of the indene ring to any extent, whether or
449 not substituted on the naphthyl ring to any extent, including,
450 but not limited to, JWH-176 (3-Pentyl-1
451 (naphthylmethylene)indene).
452 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
453 compound containing a phenylacetylindole or phenylacetylindazole
454 structure, with or without substitution on the indole or
455 indazole ring to any extent, whether or not substituted on the
456 phenyl ring to any extent, including, but not limited to:
457 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
458 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
459 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
460 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
461 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
462 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
463 (VII) Cannabipiperidiethanone.
464 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
465 methoxyphenylacetyl)indole).
466 f. Cyclohexylphenols.—Any compound containing a
467 cyclohexylphenol structure, with or without substitution at the
468 5-position of the phenolic ring to any extent, whether or not
469 substituted on the cyclohexyl ring to any extent, including, but
470 not limited to:
471 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
472 yl)phenol).
473 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
474 homologue).
475 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
476 methyloctan-2-yl)phenol).
477 g. Benzoylindoles and Benzoylindazoles.—Any compound
478 containing a benzoylindole or benzoylindazole structure, with or
479 without substitution on the indole or indazole ring to any
480 extent, whether or not substituted on the phenyl ring to any
481 extent, including, but not limited to:
482 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
483 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
484 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
485 iodo-5-nitrobenzoyl)indole).
486 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
487 methoxybenzoyl)indole).
488 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
489 iodobenzoyl)indole).
490 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
491 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
492 methoxybenzoyl)indole).
493 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
494 3-(4-methoxybenzoyl)indole).
495 h. Tetramethylcyclopropanoylindoles and
496 Tetramethylcyclopropanoylindazoles.—Any compound containing a
497 tetramethylcyclopropanoylindole or
498 tetramethylcyclopropanoylindazole structure, with or without
499 substitution on the indole or indazole ring to any extent,
500 whether or not substituted on the tetramethylcyclopropyl group
501 to any extent, including, but not limited to:
502 (I) UR-144 (1-Pentyl-3-(2,2,3,3
503 tetramethylcyclopropanoyl)indole).
504 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
505 tetramethylcyclopropanoyl)indole).
506 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
507 tetramethylcyclopropanoyl)indole).
508 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
509 tetramethylcyclopropanoyl)indole).
510 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
511 tetramethylcyclopropanoyl)indole).
512 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
513 tetramethylcyclopropanoyl)indole).
514 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
515 tetramethylcyclopropanoyl)indole).
516 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
517 tetramethylcyclopropanoyl)indazole).
518 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
519 tetramethylcyclopropanoyl)indole).
520 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
521 tetramethylcyclopropanoyl)indole).
522 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
523 carboxamides, and Adamantylindazole carboxamides.—Any compound
524 containing an adamantoyl indole, adamantoyl indazole, adamantyl
525 indole carboxamide, or adamantyl indazole carboxamide structure,
526 with or without substitution on the indole or indazole ring to
527 any extent, whether or not substituted on the adamantyl ring to
528 any extent, including, but not limited to:
529 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
530 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
531 3-carboxamide).
532 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
533 carboxamide).
534 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
535 adamantoyl)indole).
536 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
537 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
538 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
539 adamantoyl)indole).
540 j. Quinolinylindolecarboxylates,
541 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
542 and Quinolinylindazolecarboxamides.—Any compound containing a
543 quinolinylindole carboxylate, quinolinylindazole carboxylate,
544 isoquinolinylindole carboxylate, isoquinolinylindazole
545 carboxylate, quinolinylindole carboxamide, quinolinylindazole
546 carboxamide, isoquinolinylindole carboxamide, or
547 isoquinolinylindazole carboxamide structure, with or without
548 substitution on the indole or indazole ring to any extent,
549 whether or not substituted on the quinoline or isoquinoline ring
550 to any extent, including, but not limited to:
551 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
552 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
553 carboxylate).
554 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
555 carboxylate).
556 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
557 carboxylate).
558 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
559 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
560 3-carboxylate).
561 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
562 3-carboxylate).
563 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
564 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
565 carboxamide).
566 k. Naphthylindolecarboxylates and
567 Naphthylindazolecarboxylates.—Any compound containing a
568 naphthylindole carboxylate or naphthylindazole carboxylate
569 structure, with or without substitution on the indole or
570 indazole ring to any extent, whether or not substituted on the
571 naphthyl ring to any extent, including, but not limited to:
572 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
573 carboxylate).
574 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
575 carboxylate).
576 (III) Fluoro SDB-005 (1-Naphthalenyl 1
577 (fluoropentyl)indazole-3-carboxylate).
578 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
579 carboxylate).
580 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
581 carboxylate).
582 l. Naphthylindole carboxamides and Naphthylindazole
583 carboxamides.—Any compound containing a naphthylindole
584 carboxamide or naphthylindazole carboxamide structure, with or
585 without substitution on the indole or indazole ring to any
586 extent, whether or not substituted on the naphthyl ring to any
587 extent, including, but not limited to:
588 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
589 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
590 3-carboxamide).
591 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
592 (chloropentyl)indole-3-carboxamide).
593 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
594 carboxamide).
595 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
596 (fluoropentyl)indazole-3-carboxamide).
597 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
598 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
599 Alkylcarbonyl indazole carboxylates.—Any compound containing an
600 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
601 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
602 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
603 indole carboxamide, indazole carboxamide, indole carboxylate, or
604 indazole carboxylate, with or without substitution on the indole
605 or indazole ring to any extent, whether or not substituted on
606 the alkylcarbonyl group to any extent, including, but not
607 limited to:
608 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
609 pentylindole-3-carboxamide).
610 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
611 yl)-1-(fluoropentyl)indole-3-carboxamide).
612 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
613 (fluoropentyl)indole-3-carboxamide).
614 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
615 pentylindazole-3-carboxamide).
616 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
617 1-(fluoropentyl)indazole-3-carboxamide).
618 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
619 1-pentylindazole-3-carboxamide).
620 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
621 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
622 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
623 (4-fluorobenzyl)indazole-3-carboxamide).
624 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
625 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
626 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
627 (cyclohexylmethyl)indazole-3-carboxamide).
628 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
629 (cyclohexylmethyl)indazole-3-carboxamide).
630 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
631 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
632 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
633 pentylindazole-3-carboxamide).
634 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
635 (fluoropentyl)indazole-3-carboxamide).
636 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
637 fluorobenzyl)indazole-3-carboxamide).
638 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
639 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
640 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
641 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
642 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
643 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
644 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
645 fluoropentyl)indole-3-carboxamide).
646 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
647 fluoropentyl)indazole-3-carboxamide).
648 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
649 (cyclohexylmethyl)indazole-3-carboxamide).
650 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
651 fluorobenzyl)indazole-3-carboxamide).
652 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
653 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
654 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
655 Any compound containing a N-(2-phenylpropan-2-yl) indole
656 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
657 structure, with or without substitution on the indole or
658 indazole ring to any extent, whether or not substituted on the
659 phenyl ring of the cumyl group to any extent, including, but not
660 limited to:
661 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
662 carboxamide).
663 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
664 (fluoropentyl)indole-3-carboxamide).
665 o. Other Synthetic Cannabinoids.—Any material, compound,
666 mixture, or preparation that contains any quantity of a
667 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
668 (I) With or without modification or replacement of a
669 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
670 between either two core rings, or linkage between a core ring
671 and group structure, with or without the addition of a carbon or
672 replacement of a carbon;
673 (II) With or without replacement of a core ring or group
674 structure, whether or not substituted on the ring or group
675 structures to any extent; and
676 (III) Is a cannabinoid receptor agonist, unless
677 specifically excepted or unless listed in another schedule or
678 contained within a pharmaceutical product approved by the United
679 States Food and Drug Administration.
680 191. Substituted Cathinones.—Unless specifically excepted,
681 listed in another schedule, or contained within a pharmaceutical
682 product approved by the United States Food and Drug
683 Administration, any material, compound, mixture, or preparation,
684 including its salts, isomers, esters, or ethers, and salts of
685 isomers, esters, or ethers, whenever the existence of such salts
686 is possible within any of the following specific chemical
687 designations:
688 a. Any compound containing a 2-amino-1-phenyl-1-propanone
689 structure;
690 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
691 structure; or
692 c. Any compound containing a 2-amino-1-thiophenyl-1
693 propanone structure,
694
695 whether or not the compound is further modified:
696 (I) With or without substitution on the ring system to any
697 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
698 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
699 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
700 substituents;
701 (II) With or without substitution at the 3-propanone
702 position with an alkyl substituent or removal of the methyl
703 group at the 3-propanone position;
704 (III) With or without substitution at the 2-amino nitrogen
705 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
706 not further substituted in the ring system; or
707 (IV) With or without inclusion of the 2-amino nitrogen atom
708 in a cyclic structure, including, but not limited to:
709 (A) Methcathinone.
710 (B) Ethcathinone.
711 (C) Methylone (3,4-Methylenedioxymethcathinone).
712 (D) 2,3-Methylenedioxymethcathinone.
713 (E) MDPV (3,4-Methylenedioxypyrovalerone).
714 (F) Methylmethcathinone.
715 (G) Methoxymethcathinone.
716 (H) Fluoromethcathinone.
717 (I) Methylethcathinone.
718 (J) Butylone (3,4-Methylenedioxy-alpha
719 methylaminobutyrophenone).
720 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
721 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
722 (M) Naphyrone (Naphthylpyrovalerone).
723 (N) Bromomethcathinone.
724 (O) Buphedrone (alpha-Methylaminobutyrophenone).
725 (P) Eutylone (3,4-Methylenedioxy-alpha
726 ethylaminobutyrophenone).
727 (Q) Dimethylcathinone.
728 (R) Dimethylmethcathinone.
729 (S) Pentylone (3,4-Methylenedioxy-alpha
730 methylaminovalerophenone).
731 (T) Pentedrone (alpha-Methylaminovalerophenone).
732 (U) MDPPP (3,4-Methylenedioxy-alpha
733 pyrrolidinopropiophenone).
734 (V) MDPBP (3,4-Methylenedioxy-alpha
735 pyrrolidinobutyrophenone).
736 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
737 (X) PPP (Pyrrolidinopropiophenone).
738 (Y) PVP (Pyrrolidinovalerophenone) or
739 (Pyrrolidinopentiophenone).
740 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
741 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
742 (BB) F-MABP (Fluoromethylaminobutyrophenone).
743 (CC) Me-EABP (Methylethylaminobutyrophenone).
744 (DD) PBP (Pyrrolidinobutyrophenone).
745 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
746 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
747 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
748 (HH) Dimethylone (3,4-Methylenedioxy-N,N
749 dimethylcathinone).
750 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
751 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
752 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
753 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
754 (MM) Methylbuphedrone (Methyl-alpha
755 methylaminobutyrophenone).
756 (NN) Methyl-alpha-methylaminohexanophenone.
757 (OO) N-Ethyl-N-methylcathinone.
758 (PP) PHP (Pyrrolidinohexanophenone).
759 (QQ) PV8 (Pyrrolidinoheptanophenone).
760 (RR) Chloromethcathinone.
761 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
762 192. Substituted Phenethylamines.—Unless specifically
763 excepted or unless listed in another schedule, or contained
764 within a pharmaceutical product approved by the United States
765 Food and Drug Administration, any material, compound, mixture,
766 or preparation, including its salts, isomers, esters, or ethers,
767 and salts of isomers, esters, or ethers, whenever the existence
768 of such salts is possible within any of the following specific
769 chemical designations, any compound containing a phenethylamine
770 structure, without a beta-keto group, and without a benzyl group
771 attached to the amine group, whether or not the compound is
772 further modified with or without substitution on the phenyl ring
773 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
774 halide, fused alkylenedioxy, fused furan, fused benzofuran,
775 fused dihydrofuran, or fused tetrahydropyran substituents,
776 whether or not further substituted on a ring to any extent, with
777 or without substitution at the alpha or beta position by any
778 alkyl substituent, with or without substitution at the nitrogen
779 atom, and with or without inclusion of the 2-amino nitrogen atom
780 in a cyclic structure, including, but not limited to:
781 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
782 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
783 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
784 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
785 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
786 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
787 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
788 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
789 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
790 j. 2C-H (2,5-Dimethoxyphenethylamine).
791 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
792 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
793 m. MDMA (3,4-Methylenedioxymethamphetamine).
794 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
795 Methylenedioxy-N-methylbutanamine).
796 o. MDA (3,4-Methylenedioxyamphetamine).
797 p. 2,5-Dimethoxyamphetamine.
798 q. Fluoroamphetamine.
799 r. Fluoromethamphetamine.
800 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
801 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
802 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
803 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
804 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
805 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
806 y. PMA (4-Methoxyamphetamine).
807 z. N-Ethylamphetamine.
808 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
809 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
810 cc. PMMA (4-Methoxymethamphetamine).
811 dd. N,N-Dimethylamphetamine.
812 ee. 3,4,5-Trimethoxyamphetamine.
813 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
814 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
815 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
816 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
817 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
818 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
819 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
820 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
821 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
822 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
823 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
824 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
825 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
826 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
827 dihydrobenzofuran),
828
829 which does not include phenethylamine, mescaline as described in
830 subparagraph 20., substituted cathinones as described in
831 subparagraph 191., N-Benzyl phenethylamine compounds as
832 described in subparagraph 193., or methamphetamine as described
833 in subparagraph (2)(c)5.
834 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
835 excepted or unless listed in another schedule, or contained
836 within a pharmaceutical product approved by the United States
837 Food and Drug Administration, any material, compound, mixture,
838 or preparation, including its salts, isomers, esters, or ethers,
839 and salts of isomers, esters, or ethers, whenever the existence
840 of such salts is possible within any of the following specific
841 chemical designations, any compound containing a phenethylamine
842 structure without a beta-keto group, with substitution on the
843 nitrogen atom of the amino group with a benzyl substituent, with
844 or without substitution on the phenyl or benzyl ring to any
845 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
846 alkylenedioxy, fused furan, fused benzofuran, or fused
847 tetrahydropyran substituents, whether or not further substituted
848 on a ring to any extent, with or without substitution at the
849 alpha position by any alkyl substituent, including, but not
850 limited to:
851 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
852 methoxybenzyl)]phenethylamine).
853 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
854 hydroxybenzyl)]phenethylamine).
855 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
856 fluorobenzyl)]phenethylamine).
857 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
858 methylenedioxybenzyl)]phenethylamine).
859 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
860 methoxybenzyl)]phenethylamine).
861 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
862 hydroxybenzyl)]phenethylamine).
863 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
864 fluorobenzyl)]phenethylamine).
865 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
866 methylenedioxybenzyl)]phenethylamine).
867 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
868 methoxybenzyl)]phenethylamine).
869 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
870 methoxybenzyl)]phenethylamine).
871 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
872 methoxybenzyl)]phenethylamine).
873 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
874 methoxybenzyl)]phenethylamine).
875 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
876 hydroxybenzyl)]phenethylamine).
877 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
878 fluorobenzyl)]phenethylamine).
879 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
880 methylenedioxybenzyl)]phenethylamine).
881 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
882 methoxybenzyl)]phenethylamine).
883 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
884 hydroxybenzyl)]phenethylamine).
885 r. 25H-NBF (2,5-Dimethoxy-[N-(2
886 fluorobenzyl)]phenethylamine).
887 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
888 methoxybenzyl)]phenethylamine),
889
890 which does not include substituted cathinones as described in
891 subparagraph 191.
892 194. Substituted Tryptamines.—Unless specifically excepted
893 or unless listed in another schedule, or contained within a
894 pharmaceutical product approved by the United States Food and
895 Drug Administration, any material, compound, mixture, or
896 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
897 example tryptamine, structure with or without mono- or di
898 substitution of the amine nitrogen with alkyl or alkenyl groups,
899 or by inclusion of the amino nitrogen atom in a cyclic
900 structure, whether or not substituted at the alpha position with
901 an alkyl group, whether or not substituted on the indole ring to
902 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
903 groups, including, but not limited to:
904 a. Alpha-Ethyltryptamine.
905 b. Bufotenine.
906 c. DET (Diethyltryptamine).
907 d. DMT (Dimethyltryptamine).
908 e. MET (N-Methyl-N-ethyltryptamine).
909 f. DALT (N,N-Diallyltryptamine).
910 g. EiPT (N-Ethyl-N-isopropyltryptamine).
911 h. MiPT (N-Methyl-N-isopropyltryptamine).
912 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
913 j. 5-Hydroxy-N-methyltryptamine.
914 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
915 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
916 m. Methyltryptamine.
917 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
918 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
919 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
920 q. DiPT (N,N-Diisopropyltryptamine).
921 r. DPT (N,N-Dipropyltryptamine).
922 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
923 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
924 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
925 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
926 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
927 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
928 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
929 isopropyltryptamine).
930 z. Methyl-alpha-ethyltryptamine.
931 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
932
933 which does not include tryptamine, psilocyn as described in
934 subparagraph 34., or psilocybin as described in subparagraph 33.
935 195. Substituted Phenylcyclohexylamines.—Unless
936 specifically excepted or unless listed in another schedule, or
937 contained within a pharmaceutical product approved by the United
938 States Food and Drug Administration, any material, compound,
939 mixture, or preparation containing a phenylcyclohexylamine
940 structure, with or without any substitution on the phenyl ring,
941 any substitution on the cyclohexyl ring, any replacement of the
942 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
943 without substitution on the amine with alkyl, dialkyl, or alkoxy
944 substituents, inclusion of the nitrogen in a cyclic structure,
945 or any combination of the above, including, but not limited to:
946 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
947 (Benocyclidine).
948 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
949 of phencyclidine).
950 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
951 analog of phencyclidine).
952 d. PCPr (Phenylcyclohexylpropylamine).
953 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
954 analog of phencyclidine).
955 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
956 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
957 h. Methoxetamine.
958 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
959 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
960 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
961 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
962 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
963 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
964 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
965 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
966 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
967 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
968 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2
969 piperidinylidene]-benzenesulfonamide.
970 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2
971 piperidinylidene]-benzenesulfonamide.
972 198. AH-7921, 3,4-dichloro-N-[[1
973 (dimethylamino)cyclohexyl]methyl]-benzamide.
974 199. U47700, trans-3,4-dichloro-N-[2
975 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
976 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
977 dihydrochloride.
978 Section 2. This act shall take effect July 1, 2024.